07.27.07
$2.2 Billion
Key Executives:
Takashi Washi, Chairman
Akira Takahashi, President
Takahiro Kugo, Sr. Managing Executive Officer
Hachiro Hara, Sr. Managing Executive Officer
No. of Employees: 11,572
World Headquarters: Tokyo, Japan
Acquisitions and partnerships made it a defining year for Japanese medical device manufacturer Terumo Corporation, which boosted its sales by 7.4% over the prior year in the midst of corporate expansion in FY 2006 and beyond.
Terumo manufactures more than 1,500 medical products in its four Japanese-based factories and has 31 other locations throughout the world. The company’s North American headquarters is located in Somerset, NJ. With a strong international presence that shows no sign of ceasing, Terumo had sales of $2.18 billion in FY 2006, ended March 31, 2006. Net income was $286 million, up 13%.
With FY 2007, ended March 31, having closed, the company shows continued strength in annual performance. While FY 2006 had shown an increase of 7.4% over FY 2005, the company managed to grow sales by 11.9% in FY 2007, with a total of $2.362 billion.
Each of the company’s business segments have continued to grow, albeit some more so than others. Sales in the company’s Catheter and Cardiovascular System segment have grown dramatically, with a 19% rise from $785 million in FY 2006 to $935 million in FY 2007. In addition, the company’s largest source of sales, the General Hospital Products division, grew from $1.15 billion in FY 2006 to $1.18 billion in FY 2007. The Home Health Care Products division’s sales were just about flat. The company, which does not disclose individual product sales, said in a recent Web presentation that its top performers for FY 2007 were its cardiovascular systems, angiographic catheters and syringes.
The company remained steadfast in its effort to increase growth initiatives in early 2007. In January, the company completed its purchase of Chile-based company Salymed Ltda. and renamed it Terumo Chile Ltda. Since 1980, Salymed Ltda. had been the exclusive distributor of Terumo in that market and has sold syringes, blood bags and cardiovascular systems. Terumo already has 100% owned subsidiary distributors in Mexico and Brazil, and, with the addition of another overseas affiliate, the company hopes to further strengthen its presence in the Latin American market.
Terumo continued its shopping spree in March, when its subsidiary Vascutek Ltd. acquired the tissue heart valve division of Köhler Chemie Ltd. Vascutek Ltd. developed a biological valve conduit (made of biological valve and synthetic vascular graft), BioValsalva, for aortic root repair.
During this time, Terumo announced the opening of its long-anticipated new production plant in Vietnam. The company will use this facility for operations pertaining to disposable medical devices, including closed infusion systems and infusion sets. With Japan and other Asian markets a strategic focus for the company, two other plants are planned to be built on the same site.
A month later, Terumo launched a joint venture with Olympus Corp. and Olympus Biomaterial Corp. . to pursue specialization in the biomaterials market. Olympus Biomaterial Corp., which focuses on biomaterials and regenerative medicine, was integrated with Terumo’s collagen business and renamed Olympus Terumo Biomaterials Corp.
Looking ahead, the company is in the midst of awaiting CE Mark approval to launch its Norobi drug-eluting stent in Europe. (The company also received a CE Mark for its Duraheart left ventricular assist system in February.)
Key Executives:
Takashi Washi, Chairman
Akira Takahashi, President
Takahiro Kugo, Sr. Managing Executive Officer
Hachiro Hara, Sr. Managing Executive Officer
No. of Employees: 11,572
World Headquarters: Tokyo, Japan
Acquisitions and partnerships made it a defining year for Japanese medical device manufacturer Terumo Corporation, which boosted its sales by 7.4% over the prior year in the midst of corporate expansion in FY 2006 and beyond.
Terumo manufactures more than 1,500 medical products in its four Japanese-based factories and has 31 other locations throughout the world. The company’s North American headquarters is located in Somerset, NJ. With a strong international presence that shows no sign of ceasing, Terumo had sales of $2.18 billion in FY 2006, ended March 31, 2006. Net income was $286 million, up 13%.
With FY 2007, ended March 31, having closed, the company shows continued strength in annual performance. While FY 2006 had shown an increase of 7.4% over FY 2005, the company managed to grow sales by 11.9% in FY 2007, with a total of $2.362 billion.
Each of the company’s business segments have continued to grow, albeit some more so than others. Sales in the company’s Catheter and Cardiovascular System segment have grown dramatically, with a 19% rise from $785 million in FY 2006 to $935 million in FY 2007. In addition, the company’s largest source of sales, the General Hospital Products division, grew from $1.15 billion in FY 2006 to $1.18 billion in FY 2007. The Home Health Care Products division’s sales were just about flat. The company, which does not disclose individual product sales, said in a recent Web presentation that its top performers for FY 2007 were its cardiovascular systems, angiographic catheters and syringes.
The company remained steadfast in its effort to increase growth initiatives in early 2007. In January, the company completed its purchase of Chile-based company Salymed Ltda. and renamed it Terumo Chile Ltda. Since 1980, Salymed Ltda. had been the exclusive distributor of Terumo in that market and has sold syringes, blood bags and cardiovascular systems. Terumo already has 100% owned subsidiary distributors in Mexico and Brazil, and, with the addition of another overseas affiliate, the company hopes to further strengthen its presence in the Latin American market.
Terumo continued its shopping spree in March, when its subsidiary Vascutek Ltd. acquired the tissue heart valve division of Köhler Chemie Ltd. Vascutek Ltd. developed a biological valve conduit (made of biological valve and synthetic vascular graft), BioValsalva, for aortic root repair.
During this time, Terumo announced the opening of its long-anticipated new production plant in Vietnam. The company will use this facility for operations pertaining to disposable medical devices, including closed infusion systems and infusion sets. With Japan and other Asian markets a strategic focus for the company, two other plants are planned to be built on the same site.
A month later, Terumo launched a joint venture with Olympus Corp. and Olympus Biomaterial Corp. . to pursue specialization in the biomaterials market. Olympus Biomaterial Corp., which focuses on biomaterials and regenerative medicine, was integrated with Terumo’s collagen business and renamed Olympus Terumo Biomaterials Corp.
Looking ahead, the company is in the midst of awaiting CE Mark approval to launch its Norobi drug-eluting stent in Europe. (The company also received a CE Mark for its Duraheart left ventricular assist system in February.)